LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

Search

Certara Inc

Închisă

SectorSănătate

8.56 -0.58

Rezumat

Modificarea prețului

24h

Curent

Minim

8.4

Maxim

9

Indicatori cheie

By Trading Economics

Venit

-6.7M

-2M

Vânzări

-1.4M

105M

P/E

Medie Sector

234

77.256

Marjă de profit

-1.882

Angajați

1,487

EBITDA

29M

30M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+67.24% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

267M

1.9B

Deschiderea anterioară

9.14

Închiderea anterioară

8.56

Sentimentul știrilor

By Acuity

94%

6%

361 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Certara Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 nov. 2025, 22:17 UTC

Câștiguri

Commonwealth Bank Posts Flat 1Q Profit Despite Margin Pressure -- Update

10 nov. 2025, 21:48 UTC

Câștiguri

Commonwealth Bank Posts Flat 1Q Profit Despite Margin Pressure

10 nov. 2025, 23:44 UTC

Market Talk

Gold Edges Higher on Signs of Possible End to U.S. Govt Shutdown -- Market Talk

10 nov. 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

10 nov. 2025, 22:20 UTC

Achiziții, Fuziuni, Preluări

Paramount Stock Climbs as Forecast Beats Estimates -- Barrons.com

10 nov. 2025, 21:50 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

10 nov. 2025, 21:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

10 nov. 2025, 21:49 UTC

Achiziții, Fuziuni, Preluări

Paramount Stock Climbs as Forecast Beats Estimates -- Barrons.com

10 nov. 2025, 21:45 UTC

Câștiguri

PepsiCo and 3 Other Defensive Stocks to Ride Out a Vulnerable Market -- Barrons.com

10 nov. 2025, 21:40 UTC

Câștiguri

Friedman Industries 2Q EPS 32c >FRD

10 nov. 2025, 21:18 UTC

Câștiguri

Occidental Petroleum 3Q Adj EPS 64c >OXY

10 nov. 2025, 21:17 UTC

Câștiguri

Occidental Petroleum 3Q EPS 65c >OXY

10 nov. 2025, 21:17 UTC

Câștiguri

Occidental Petroleum 3Q Rev $6.72B >OXY

10 nov. 2025, 21:16 UTC

Câștiguri

Occidental Petroleum 3Q EPS 65c >OXY

10 nov. 2025, 21:16 UTC

Câștiguri

Occidental Petroleum 3Q Adj EPS 64c >OXY

10 nov. 2025, 20:30 UTC

Market Talk

Expected End to U.S. Government Shutdown Helps Lift Crude -- Market Talk

10 nov. 2025, 20:24 UTC

Market Talk

Hopes For New Government Data Lift Gold -- Market Talk

10 nov. 2025, 20:08 UTC

Market Talk

U.S. Natural Gas Settles Higher As Colder Weather Arrives -- Market Talk

10 nov. 2025, 19:49 UTC

Market Talk

Mexican Industrial Production Seen Soft in September -- Market Talk

10 nov. 2025, 19:43 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Paramount Earnings Come Amid Warner Bros Merger Reports -- Barrons.com

10 nov. 2025, 19:16 UTC

Câștiguri

Charles Schwab's CEO Is Worried About Prediction Markets. What He Told Thousands of Financial Advisors. -- Barrons.com

10 nov. 2025, 17:58 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly Stock on Pace for a New High. The Zepbound Maker Just Got a Big Upgrade. -- Barrons.com

10 nov. 2025, 17:56 UTC

Market Talk

Oil Futures Edge Up in Rangebound Trade -- Market Talk

10 nov. 2025, 17:32 UTC

Câștiguri

Barrick Looking to Reset Safety Culture Following Fatalities -- Interview

10 nov. 2025, 17:30 UTC

Câștiguri

Barrick Continues Efforts to Free Workers Jailed in Mali -- Interview

10 nov. 2025, 17:20 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

10 nov. 2025, 17:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

10 nov. 2025, 17:00 UTC

Câștiguri

Barrick Looks to Get Handle On North American Operations, Find Growth -- Interview

10 nov. 2025, 17:00 UTC

Câștiguri

Barrick Expects Strong Cash Flows Ahead With Commodity Prices at Current Levels, CFO Says in Interview

10 nov. 2025, 17:00 UTC

Câștiguri

Barrick Conducting Bottom-Up Review of Nevada Ops, Looking for Growth Opportunities

Comparație

Modificare preț

Certara Inc Așteptări

Obiectiv de preț

By TipRanks

67.24% sus

Prognoză pe 12 luni

Medie 14.5 USD  67.24%

Maxim 16 USD

Minim 12 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCertara Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

8 ratings

4

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

11.27 / 12.79Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

361 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat